X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PANACEA BIOTECH - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PANACEA BIOTECH DISHMAN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 178.0 14.1% View Chart
P/BV x 3.3 4.0 84.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
DISHMAN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs374149 251.8%   
Low Rs12982 156.6%   
Sales per share (Unadj.) Rs197.884.1 235.1%  
Earnings per share (Unadj.) Rs21.2-18.3 -115.8%  
Cash flow per share (Unadj.) Rs34.7-6.7 -518.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.983.7 214.9%  
Shares outstanding (eoy) m80.6961.25 131.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.4 92.7%   
Avg P/E ratio x11.9-6.3 -188.1%  
P/CF ratio (eoy) x7.2-17.2 -42.0%  
Price / Book Value ratio x1.41.4 101.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3067,074 287.0%   
No. of employees `0000.82.8 30.1%   
Total wages/salary Rs m5,3551,449 369.5%   
Avg. sales/employee Rs Th19,252.71,874.1 1,027.3%   
Avg. wages/employee Rs Th6,459.5527.0 1,225.7%   
Avg. net profit/employee Rs Th2,064.1-407.7 -506.2%   
INCOME DATA
Net Sales Rs m15,9615,154 309.7%  
Other income Rs m265100 265.9%   
Total revenues Rs m16,2265,254 308.9%   
Gross profit Rs m4,103-766 -535.5%  
Depreciation Rs m1,091711 153.4%   
Interest Rs m9441,503 62.8%   
Profit before tax Rs m2,334-2,881 -81.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m1-6 -19.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m62417 3,711.9%   
Profit after tax Rs m1,711-1,121 -152.6%  
Gross profit margin %25.7-14.9 -172.9%  
Effective tax rate %26.7-0.6 -4,581.8%   
Net profit margin %10.7-21.8 -49.3%  
BALANCE SHEET DATA
Current assets Rs m11,0183,810 289.2%   
Current liabilities Rs m9,5178,365 113.8%   
Net working cap to sales %9.4-88.4 -10.6%  
Current ratio x1.20.5 254.2%  
Inventory Days Days110156 71.0%  
Debtors Days Days3567 51.8%  
Net fixed assets Rs m16,30414,480 112.6%   
Share capital Rs m16161 263.3%   
"Free" reserves Rs m12,907903 1,429.2%   
Net worth Rs m14,5165,127 283.1%   
Long term debt Rs m4,1895,832 71.8%   
Total assets Rs m29,80519,433 153.4%  
Interest coverage x3.5-0.9 -378.7%   
Debt to equity ratio x0.31.1 25.4%  
Sales to assets ratio x0.50.3 201.9%   
Return on assets %8.92.0 453.6%  
Return on equity %11.8-21.9 -53.9%  
Return on capital %17.53.6 482.1%  
Exports to sales %24.824.5 101.1%   
Imports to sales %3.710.2 36.7%   
Exports (fob) Rs m3,9561,264 313.0%   
Imports (cif) Rs m596525 113.6%   
Fx inflow Rs m4,9521,539 321.7%   
Fx outflow Rs m697942 74.0%   
Net fx Rs m4,255597 712.4%   
CASH FLOW
From Operations Rs m2,786599 465.0%  
From Investments Rs m-1,529-438 349.1%  
From Financial Activity Rs m-941-303 311.0%  
Net Cashflow Rs m316-141 -223.9%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 12.7 1.3 976.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 23.6 93.6%  
Shareholders   46,261 10,259 450.9%  
Pledged promoter(s) holding % 35.8 35.1 102.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Continues Momentum; Metal Sector Up 2.5%(11:30 am)

After opening the day on a positive note, stock markets in India have continued their momentum. Sectoral indices are trading on a positive note with stocks in the metal sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS